Adverse events: research and patient questions

This study followed 192 adults in the United Kingdom who had long-lasting pain from arthritis and were given medicinal cannabis by a private clinic. Each person filled in questionnaires about pain, mood, sleep and daily life over two years. The researchers looked at how these answers changed over time.

This study looked at how safe it is for people who drink alcohol moderately to also use a substance called cannabidiol (CBD). The researchers tested this in two settings: a lab and in people's homes over a longer period.

While adjunctive transdermal cannabidiol (ZYN002) at doses of 195 mg or 390 mg daily did not demonstrate statistically significant superiority over placebo in reducing focal seizure frequency over 12 weeks, it exhibited an excellent safety and tolerability profile with minimal gastrointestinal or hepatic adverse events. The favorable long-term tolerability and signals of seizure reduction in the open-label extension suggest that future clinical trials evaluating higher doses of transdermal cannabidiol in adult focal epilepsy are warranted.

Low-dose oral synthetic cannabidiol (20-30 mg daily) failed to provide clinically meaningful pain relief or improve sleep and mood scores compared to placebo in patients with hand osteoarthritis or psoriatic arthritis. Integrative clinicians should recognize that conservative low-dose CBD monotherapy is unlikely to suffice for moderate-to-severe arthritic pain, and higher dosages or full-spectrum formulations should be formally evaluated in future adequately powered trials.

Clinicians should be cautious when prescribing CBD-dominant cannabis products, as they may produce stronger adverse effects than expected. Understanding cannabinoid interactions is crucial for safe therapeutic use.

Clinicians should be aware that while CBD may increase the psychoactive effects of THC, it does not enhance its analgesic properties. Careful consideration of dosing is essential when combining these cannabinoids.

Sublingual THC:CBD oil extracts administered at modest, individually titrated daily doses (around 20 mg each) provided statistically significant, modest long-term improvements in chronic pain and associated disease burden (sleep, anxiety, and quality of life) with a reasonable safety profile. However, nearly 40% of patients dropped out by 6 months, and clinician monitoring for CNS and GI side effects remains essential.

While purified CBD is generally well-tolerated in clinical trials, the widespread availability of unregulated CBD-infused foods presents safety risks due to unpredictable dosing, lack of extract standardization, and pronounced increases in bioavailability when consumed with dietary fats. Integrative clinicians should counsel patients on the variability and lack of federal safety oversight in commercial CBD food products, keeping potential drug-drug interactions and elevated liver enzyme risks in mind.

Clinicians should be cautious when prescribing cannabinoid-based medicines to older adults due to the limited data on adverse events. Monitoring for potential adverse effects is essential.